Ingram D
University Department of Surgery, Queen Elizabeth II Medical Centre, Perth, Western Australia.
Aust N Z J Surg. 1990 Sep;60(9):673-5. doi: 10.1111/j.1445-2197.1990.tb07454.x.
Tamoxifen is widely used in the management of breast cancer, including long-term use in women with early disease to reduce recurrence and mortality. Although remarkably side-effect free, concern has been expressed that its anti-oestrogen activity may extend to lipid metabolism and so result in the premature development of coronary heart disease. In a study of breast cancer patients, those taking Tamoxifen tended to have lower cholesterol concentrations (predominantly low-density lipoprotein cholesterol) and raised triglyceride concentrations. These changes are likely to be protective for coronary heart disease, suggesting Tamoxifen has an oestrogenic rather than anti-oestrogenic effect as regards lipid metabolism.
他莫昔芬被广泛用于乳腺癌的治疗,包括长期用于早期疾病的女性以降低复发率和死亡率。尽管其副作用极小,但有人担心其抗雌激素活性可能会扩展到脂质代谢,从而导致冠心病过早发展。在一项针对乳腺癌患者的研究中,服用他莫昔芬的患者往往胆固醇浓度较低(主要是低密度脂蛋白胆固醇)且甘油三酯浓度升高。这些变化可能对冠心病具有保护作用,这表明就脂质代谢而言,他莫昔芬具有雌激素样而非抗雌激素样作用。